51. Treatment of cutaneous sarcoidosis with thalidomide.
- Author
-
Nguyen YT, Dupuy A, Cordoliani F, Vignon-Pennamen MD, Lebbé C, Morel P, and Rybojad M
- Subjects
- Adult, Dose-Response Relationship, Drug, Female, Humans, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents adverse effects, Male, Middle Aged, Retrospective Studies, Sarcoidosis pathology, Skin Diseases pathology, Thalidomide administration & dosage, Thalidomide adverse effects, Treatment Outcome, Venous Thrombosis chemically induced, Immunosuppressive Agents therapeutic use, Sarcoidosis drug therapy, Skin Diseases drug therapy, Thalidomide therapeutic use
- Abstract
Background: Although systemic corticosteroids are effective against cutaneous sarcoidosis, alternative therapies are needed., Objective: We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis., Methods: We performed a retrospective evaluation of thalidomide (100-200 mg/d) in 12 consecutive patients with cutaneous sarcoidosis treated in a university hospital between 2000 and 2002., Results: Cutaneous lesions regressed within 1 to 5 months, with an average time of 2 to 3 months for 10 patients. In all, 4 patients achieved complete responses, 6 had partial responses, and 2 had no regression. Nasopharyngeal, pulmonary neurologic, and hepatic symptoms were also attenuated. Thalidomide was well tolerated. The main adverse effect was deep vein thrombosis in 1 patient., Conclusion: Thalidomide efficacy and tolerance in patients with cutaneous sarcoidosis merits further evaluation in a controlled trial.
- Published
- 2004
- Full Text
- View/download PDF